Clinical trials: B Cell
Diffuse Large B-cell Lymphoma
R-CHOP Alone vs. R-CHOP Plus Radiotherapy for Localized CD20+ DLBCL
To compare the efficacy and safety of chemotherapy alone and combined modality therapy in the treatment of localized CD20 (+) diffuse large B-cell lymphoma
- Trial name
- ASPIRE (NCT02054559)
- Testing
- R-CHOP, Radiotherapy
- Where
- South Korea
- Sponsor
- Asan Medical Center
Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
A Study of Pirtobrutinib (LOXO-305) Versus Bendamustine Plus Rituximab (BR) in Untreated Patients With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)
The purpose of this study is to compare the efficacy and safety of pirtobrutinib (LOXO-305; Arm A) compared to BR (Arm B) in patients with CLL/SLL who have not been treated. Participation could last up to five years.
- Trial name
- BRUIN-CLL-313 (NCT05023980)
- Testing
- Pirtobrutinib, Bendamustine, Rituximab
- Where
- 108 sites in United States, Australia and 18 more
- Volunteers
- 282 people
- Sponsor
- Loxo Oncology, Inc.
Lymphomatoid Granulomatosis, Granulomatosis, Lymphomatoid
Treatment and Natural History Study of Lymphomatoid Granulomatosis
This study will evaluate the response and long-term effects of alpha-interferon in patients with lymphomatoid granulomatosis (LYG).
- Conditions
- Lymphomatoid Granulomatosis, Granulomatosis, Lymphomatoid, Non-Hodgkins Lymphoma, Lymphoproliferative Disorder
- Trial name
- NCT00001379
- Testing
- Interferon, Rituxan and EPOCH, Tumor biopsy
- Where
- United States
- Volunteers
- 94 people
- Sponsor
- National Cancer Institute (NCI)
Non-Hodgkin Lymphoma
Safety and Efficacy of Entospletinib (ENTO [GS-9973]) Combined With Vincristine (VCR) in Adult Participants With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma (NHL)
The primary objective of this study is to evaluate the safety of ENTO with VCR in participants with relapsed or refractory B-cell NHL.
- Trial name
- NCT02568683
- Testing
- Entospletinib, Vincristine
- Where
- 7 sites in United States, France
- Volunteers
- 10 people
- Sponsor
- Gilead Sciences
Acute Lymphoblastic Leukemia, Acute Lymphoblastic Leukemia, in Relapse
Study of Sequential CAR-T Cell Treating Leukemia Children
The investigators will conduct a phase II clinical trial of sequential chimeric antigen receptor T cell targeting at different B-cell antigens in refractory or relapsed B-cell acute lymphoblastic leukemia children in Beijing…
- Conditions
- Acute Lymphoblastic Leukemia, Acute Lymphoblastic Leukemia, in Relapse, Refractory Acute Lymphoid Leukemia
- Trial name
- NCT04340154
- Testing
- chimeric antigen receptor T cell
- Where
- China
- Volunteers
- 81 people
- Sponsor
- Beijing Boren Hospital
B-Cell Lymphoma
Treatment of Mature B-cell Lymphoma/Leukaemia
This is an international trial conducted by three cooperative groups: SFOP (France, Belgium, Netherlands), CCG (USA, Canada, Australia), and UKCCSG (UK and Ireland).
- Trial name
- NCT00162656
- Testing
- half cyclophosphamide, without COPADM3, mini CYVE, without 3 maintenance courses
- Where
- 3 sites in United States, France and 1 more
- Volunteers
- 848 people
- Sponsor
- Gustave Roussy, Cancer Campus, Grand Paris
Diffuse Large B-cell Lymphoma
A Phase 3 Clinical Study of SHR-A1912 Combined With R-GemOx Versus R-GemOx in Diffuse Large B-cell Lymphoma
This is a multicenter, randomized, open-label, phase 3 clinical study to evaluate the efficacy of SHR-A1912 combined with R-GemOx in relapsed refractory diffuse large B-cell lymphoma.
- Trial name
- NCT06929624
- Testing
- SHR-A1912 Injection, Rituximab Injection, Gemcitabine Hydrochloride for Injection
- Where
- 2 sites in China
- Volunteers
- 282 people
- Sponsor
- Suzhou Suncadia Biopharmaceuticals Co., Ltd.
Leukemia, Myeloid, Acute, Leukemia, Lymphocytic, Acute, T-Cell
Pilot Study of Expanded, Donor Natural Killer Cell Infusions for Refractory Non-B Lineage Hematologic Malignancies and Solid Tumors
Modern frontline therapy for patients with hematologic malignancies is based on intensive administration of multiple drugs. In patients with relapsed disease, response to the same drugs is generally poor, and dosages cannot be…
- Conditions
- Leukemia, Myeloid, Acute, Leukemia, Lymphocytic, Acute, T-Cell, Juvenile Myelomonocytic Leukemia Lymphoblastic, T-cell Lymphoblastic Lymphoma
- Trial name
- NCT00640796
- Testing
- Haploidentical donor derived natural killer cell infusion, Chemotherapy, CliniMACS
- Where
- United States
- Volunteers
- 22 people
- Sponsor
- St. Jude Children's Research Hospital
STAGE IIIA/B NSCLC / INOPERABLE LUNG CANCER
Phase I/II NabPaclitaxel, Paclitaxel&Carboplatin w RTX Followed by Consolidation in Patients w Favorable Prognosis Inoperable Stage IIIA/B NSCLC
The investigators propose this phase I/II study to use weekly Nab-Paclitaxel (Abraxane) and carboplatin with concurrent radiation in local-regionally advanced lung cancer.
- Trial name
- NCT01757288
- Testing
- NAB-PACLITAXEL, PACLITAXEL
- Where
- 5 sites in United States
- Volunteers
- 98 people
- Sponsor
- University of Texas Southwestern Medical Center
Leukemia, Lymphocytic, Chronic, B-Cell
Treatment of Chronic Lymphocytic Leukemia
CLL is a disease of the elderly, identifying effective therapies with better toxicity profiles is thus a high priority, and targeted therapies may allow attainment of this goal.
- Trial name
- NCT02757586
- Testing
- shRNA
- Volunteers
- 70 people, healthy volunteers welcome
- Sponsor
- Peking University People's Hospital
Sickle Cell Disease, Sickle Cell Hemoglobin C
Home-based Assessment of PRO Measures in SCD Using A Smartphone App Platform: A Feasibility Study
The overarching goal of this proposal is to identify modifiable behavioral strategies based on patient-reported outcomes (PROs) and health-related quality of life (HRQOL) that will improve hydroxyurea (HU) adherence among…
- Conditions
- Sickle Cell Disease, Sickle Cell Hemoglobin C, Sickle Beta Zero Thalassemia, Sickle B+ Thalassemia
- Trial name
- NCT04678037
- Testing
- PROs assessment using sickle cell disease mobile app (SCD-app)
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- Ann & Robert H Lurie Children's Hospital of Chicago
Chronic Lymphocytic Leukemia, Indolent B-Cell Non-Hodgkin Lymphoma
Incidence of Severe COVID-19 Infection in Patients With CLL or B-NHL Who Received Pre-exposure Prophylaxis With Tixagevimab and Cilgavimab in Italy.
This is an observational retrospective and prospective multicenter study aimed at describing the role of the COVID -19 prophylaxis with Tixagevimab and Cilgavimab in CLL or indolent B-NHL patients who received first COVID-19…
- Conditions
- Chronic Lymphocytic Leukemia, Indolent B-Cell Non-Hodgkin Lymphoma, COVID-19
- Trial name
- NCT05803395
- Where
- 15 sites in Italy
- Volunteers
- 954 people
- Sponsor
- Gruppo Italiano Malattie EMatologiche dell'Adulto
B-cell Acute Lymphoblastic Leukemia
Phase 1/2 Study of UCART22 in Patients With Relapsed or Refractory CD22+ B-cell Acute Lymphoblastic Leukemia (BALLI-01)
This is a first-in-human, open-label, dose escalation and expansion study of UCART22 administered intravenously to patients with relapsed or refractory B-cell acute Lymphoblastic Leukemia (B-ALL).
- Trial name
- NCT04150497
- Testing
- UCART22, CLLS52
- Where
- 19 sites in United States, France
- Volunteers
- 52 people
- Sponsor
- Cellectis S.A.
Chronic Lymphocytic Leukemia
FCM-R (Fludarabine, Cyclophosphamide, Mitoxantrone, Rituximab) in Previously Untreated Patients With Chronic Lymphocytic Leukemia (CLL) < 70 Years
The goal of this clinical research study is to learn if using a combination of fludarabine, cyclophosphamide, and mitoxantrone plus rituximab, with the growth factor pegylated filgrastim, will improve the response to treatment…
- Trial name
- NCT00254410
- Testing
- Fludarabine, Cyclophosphamide, Mitoxantrone
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- M.D. Anderson Cancer Center
Large B-cell Lymphoma, Follicular Lymphoma
Expanded Access Study for the Treatment of Patients With Commercially Out-of-Specification Axicabtagene Ciloleucel
The goal of this study is to provide access to axicabtagene ciloleucel for patients diagnosed with a disease approved for treatment with axicabtagene ciloleucel, that is otherwise out of specification for commercial release.
- Trial name
- NCT05776160
- Testing
- Axicabtagene Ciloleucel
- Where
- 128 sites in United States, Japan
- Sponsor
- Kite, A Gilead Company
B-cell Malignancies
Study of the Safety and Pharmacokinetics of BGB-3111 in Subjects With B-Cell Lymphoid Malignancies
This study evaluated the safety, tolerability, pharmacokinetic profile and efficacy of BGB-3111 in participants with B-cell lymphoid malignancies.
- Trial name
- NCT02343120
- Testing
- Zanubrutinib
- Where
- 23 sites in United States, Australia and 4 more
- Volunteers
- 385 people
- Sponsor
- BeiGene
Chronic Lymphocytic Leukemia
A Phase 2 Open-Label Study of the Efficacy and Safety of ABT-199 (GDC-0199) in Chronic Lymphocytic Leukemia (CLL) Subjects With Relapse or Refractory to B-Cell Receptor Signaling Pathway Inhibitor Therapy
This was an open-label, non-randomized, multicenter, Phase 2 study evaluating the efficacy and safety of ABT-199 in 127 participants with relapsed or refractory chronic lymphocytic leukemia (CLL) after B-cell receptor signaling…
- Trial name
- NCT02141282
- Testing
- Venetoclax
- Where
- 15 sites in United States
- Volunteers
- 127 people
- Sponsor
- AbbVie
Accelerated Phase Chronic Myelogenous Leukemia, Adult Acute Lymphoblastic Leukemia in Remission
Internet-Based Program With or Without Telephone-Based Problem-Solving Training in Helping Long-Term Survivors of Hematopoietic Stem Cell Transplant Cope With Late Complications
RATIONALE: A personalized Internet-based program may help improve fatigue, depression, and quality of life in long-term survivors of stem cell transplant.
- Conditions
- Accelerated Phase Chronic Myelogenous Leukemia, Adult Acute Lymphoblastic Leukemia in Remission, Adult Acute Myeloid Leukemia in Remission, Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities
- Trial name
- NCT00799461
- Testing
- internet-based intervention, questionnaire administration, psychosocial assessment and care
- Where
- United States
- Volunteers
- 1,337 people
- Sponsor
- Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium
B Cell Malignancies
Anti-CD19-CAR-T Cells in Relapsed/Refractory B-cell Tumor Patients.
This study is a single-center, open-label, single-dose clinical trial of anti-CD19-CAR-T cell therapy in relapsed/refractory B-cell tumor patients after Qinglin pre-treatment.
- Trial name
- NCT06375161
- Testing
- anti-CD19-CAR-T cells
- Where
- China
- Volunteers
- 12 people
- Sponsor
- Shanghai Tongji Hospital, Tongji University School of Medicine
B-lymphoid Malignancies, Chronic Lymphocytic Leukemia
Study of Intravenously Administered SNS-032 in Patients With Advanced B-lymphoid Malignancies
The purpose of this study is to assess the safety and tolerability of escalating doses of SNS-032, given in 3 weekly administrations per cycle and to identify a recommended Phase 2 dose.
- Conditions
- B-lymphoid Malignancies, Chronic Lymphocytic Leukemia, Mantle Cell Lymphoma, Multiple Myeloma
- Trial name
- NCT00446342
- Testing
- SNS-032 Injection
- Where
- 6 sites in United States
- Volunteers
- 21 people
- Sponsor
- Sunesis Pharmaceuticals
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.